Requires continued coverage of prescription drugs for certain medical conditions.
Impact
If passed, A1590 would significantly affect existing health insurance policies, mandating that coverage be maintained for these groups throughout any stage of the appeals process. Under the proposed legislation, insurers would not be allowed to impose limitations on maximum coverage or impose higher out-of-pocket costs during the appeal of coverage denial for the specified conditions. This is aimed at protecting vulnerable populations from losing access to essential medications while disputes regarding medical necessity are resolved.
Summary
Assembly Bill A1590 requires health insurance providers in New Jersey to continue coverage for prescription drugs when individuals diagnosed with complex or chronic medical conditions or rare diseases appeal coverage denials based on medical necessity. The bill defines 'complex or chronic medical condition' as conditions that lack a known cure or that might be severely debilitating or fatal if not properly treated. A 'rare disease' is defined as one affecting fewer than 200,000 people in the U.S. The intent is to ensure that individuals can have access to necessary medications during the appeals process, without facing additional limitations or increased costs based on their insurance contracts.
Contention
The legislation presents potential challenges, particularly for insurance companies which may argue that it imposes significant burdens by restricting their ability to manage drug coverage proactively. Additionally, concerns may arise about the qualifications for what constitutes a 'complex' condition, and whether this will lead to an influx of appeals, straining resources. Opponents may also worry about the implications of increased drug costs resulting from mandatory coverage requirements, potentially affecting the overall healthcare system.
Prohibits SHBP, SEHBP, and Medicaid from denying coverage for maintenance medications for chronic conditions for covered persons solely because of change in health benefits plan or pharmacy benefits manager.
Requires unrestricted Medicaid coverage for ovulation enhancing drugs and medical services related to administering such drugs for certain beneficiaries experiencing infertility.